Skip to main content
Concord Biotech Limited logo

Concord Biotech Limited — Investor Relations & Filings

Ticker · CONCORDBIO ISIN · INE338H01029 LEI · 335800FBIZZTLAXLXZ73 BSE.NS Manufacturing
Open in API
Filings indexed 225 across all filing types
Latest filing 2025-03-18 Regulatory Filings
Country IN India
Listing BSE.NS CONCORDBIO

About Concord Biotech Limited

https://concordbiotech.com/

Concord Biotech Limited is a research and development-driven company specializing in the production of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization focuses on niche therapeutic areas, including immunosuppressants, oncology, anti-fungals, and anti-infectives. It maintains a significant global presence, supplying products to regulated markets such as the United States, Europe, and Japan. Concord Biotech operates large-scale fermentation facilities and is recognized for its expertise in complex manufacturing processes. Its operations are vertically integrated, covering the entire value chain from strain development and fermentation to downstream processing and formulation. The company adheres to international quality standards, holding certifications from major regulatory bodies like the USFDA and EUGMP, ensuring the delivery of high-quality pharmaceutical solutions to its global clientele.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification to stock exchanges about the schedule of analyst and institutional investor meetings. It explicitly states that the discussions will be based on publicly available information and no unpublished price sensitive information will be discussed. The document is an intimation under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30(6), which pertains to disclosure of events or information. The document does not contain any financial data, report, or detailed presentation but is an announcement of a meeting schedule. It is not a report, earnings release, or investor presentation itself. Given the nature and length of the document (2191 characters), it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-03-18 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal communication from Concord Biotech Limited to stock exchanges (NSE and BSE) informing about the schedule of analyst and institutional investor meetings. It explicitly states that the discussions will be based on publicly available information and no unpublished price sensitive information will be discussed. The document is an intimation or announcement about upcoming meetings, not a report or transcript of the meetings themselves. It is short (2078 characters) and serves as a regulatory disclosure under SEBI Listing Obligations and Disclosure Requirements. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain financial data, detailed presentations, or meeting transcripts.
2025-03-10 English
Outcome of Board Meeting
Capital/Financing Update Classification · 95% confidence The document is a formal communication from Concord Biotech Limited to stock exchanges (NSE and BSE) regarding the outcome of a Board Meeting held on March 4, 2025. The main content is the approval of an investment in Clean Max Everglades Pvt Ltd for installation of a hybrid renewable energy plant. The document includes detailed disclosures as per Regulation 30 of SEBI LODR Regulations, describing the investment, shareholding, and background of the target entity. There are no financial statements or detailed financial performance data presented. The document is an announcement of a corporate action (investment/financing) approved by the Board, not a full financial report or earnings release. It fits the category of Capital/Financing Update (CAP) as it informs about a significant investment and capital allocation decision by the company.
2025-03-04 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal communication from Concord Biotech Limited to stock exchanges (NSE and BSE) regarding the schedule of analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, and explicitly states the nature of the meetings and that no unpublished price sensitive information will be discussed. The document is an intimation or announcement about upcoming investor meetings rather than a financial report, earnings release, or detailed presentation. It does not contain financial data, management discussion, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2025-03-01 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice (2023 characters) informing stock exchanges about the schedule of analyst and institutional investor meetings. It explicitly states that discussions will be based on publicly available information and no unpublished price sensitive information will be discussed. The document is an intimation under SEBI regulations about upcoming investor meetings, not a financial report or transcript of the meetings themselves. It does not contain financial data, earnings, or detailed presentations. Therefore, it is an announcement related to investor meetings, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-02-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of the Q3 FY 2025 earnings conference call of Concord Biotech Limited held on February 14, 2025. It includes management commentary on financial performance, segmental revenue breakdowns, strategic updates, and outlook. The text explicitly mentions it is a transcript of the earnings call, with multiple speakers including the CEO and CFO discussing quarterly and nine-month financial results, business strategy, and investments. The document length is substantial (15,000 characters), and it contains substantive financial data and analysis, not just an announcement or summary. Therefore, this document fits the definition of a Call Transcript (CT).
2025-02-21 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.